Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Elotuzumab Plus Pomalidomide and Dexamethasone in Relapsed/refractory Multiple Myeloma: Extended Follow-Up of a Multicenter, Retrospective Real-World Experience with 321 Cases Outside of Controlled Clinical Trials.

Enrica Antonia Martino,Salvatore Palmieri,Monica Galli,Daniele Derudas,Roberto Mina,Roberta Della Pepa,Renato Zambello,Ernesto Vigna,Antonella Bruzzese,Silvia Mangiacavalli,Elena Zamagni,Catello Califano,Maurizio Musso,Concetta Conticello,Claudio Cerchione,Giuseppe Mele,Nicola Di Renzo,Massimo Offidani,Giuseppe Tarantini,Gloria Margiotta Casaluci,Angela Rago,Roberto Ria,Giuseppina Uccello,Gregorio Barila,Gaetano Palumbo,Loredana Pettine,Iolanda Donatella Vincelli,Marino Brunori,Fabrizio Accardi,Valeria Amico,Angela Amendola,Raffaele Fontana,Velia Bongarzoni,Bernardo Rossini,Emilia Cotzia,Alessandro Gozzetti,Rita Rizzi,Nicola Sgherza,Giovanni Reddiconto,Antonio Maroccia,Luca Franceschini,Giuseppe Bertuglia,Davide Nappi,Emiliano Barbieri,Barbara Gamberi,Maria Teresa Petrucci,Francesco Di Raimondo,Antonino Neri,Fortunato Morabito,Pellegrino Musto,Massimo Gentile

HEMATOLOGICAL ONCOLOGY（2024）

Cited 3|Views26
Key words
dexamethasone,elotuzumab,multiple myeloma,pomalidomide,salvage therapy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined